Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Resistant Recurrent Ovarian Cancer: KOV-02R - Resistant Cancer of Ovary (RECOVER)

NCT05316181 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT05316181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05316181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Resistant Recurrent Ovarian Cancer: KOV-02R - Resistant Cancer of Ovary (RECOVER)
Lead sponsor
National Cancer Center, Korea
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 7, 2022
Completion date
December 31, 2029
Enrollment
140 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cytoreductive surgery, epithelial ovarian cancer, hipec, mitomycin, platinum resistant, recurrent ovarian